Abstract

Objective: This study aimed to investigate the effects of tirzepatide on obesity and identify any reported side effects.
Methods: This was a retrospective cohort study of patients with morbid obesity who received tirzepatide injections from 2022 to 2024 in the Al Madinah region. An online questionnaire was sent to individuals who had received tirzepatide injections in the Al Madinah r egion.
Results: The study involved 273 participants. The mean weight decreased from 88.4 ± 10.1 kg before treatment to 68.8 ± 19.1 kg after treatment. The mean body mass index (BMI) dropped from 33.5 ± 9.8 kg/m² before treatment to 24.9 ± 6.3 kg/m² after treatment. Side effects, injection frequency, significantly associated with headaches, diarrhea, holding, and fever (p < 0.05). Medication dose was significantly associated with skin rash and inflammation. Treatment generally improves the quality of life. However, there was a negative impact on strenuous activities and the need to stay in bed or a chair throughout the day.
Conclusion: Tirzepatide is a safe and effective medication for weight loss with minimal complications. Treatment not only leads to significant reductions in weight and BMI but also positively impacts patients' overall quality of life.

Key words: Obesity, BMI, Tirzepatide, GLP-1, weight loss